TABLE 2.
Characteristics of the “Vienna cohort” at the time of HVPG measurement and comparison between patients with O and non‐O blood types
| Patient characteristics | All patients, n = 411 | O, n = 147 | Non‐O, n = 264 | P value |
|---|---|---|---|---|
| Age, y | 54.1 ± 11.4 | 54.1 ± 11.2 | 54.1 ± 11.5 | .954 |
| Sex | ||||
| Male | 286 (70%) | 100 (68%) | 186 (70%) | .608 |
| Female | 125 (30%) | 47 (32%) | 78 (30%) | |
| BMI, kg × m−2 | 26 (6.4) | 25.7 (5.7) | 26.2 (7.2) | .3 |
| Overweight a | 237 (58%) | 82 (56%) | 155 (59%) | .564 |
| Obesity b | 88 (21%) | 23 (16%) | 65 (25%) | .034 |
| Arterial hypertension | 112 (27%) | 36 (25%) | 76 (29%) | .348 |
| Diabetes mellitus | 92 (22%) | 31 (21%) | 61 (23%) | .638 |
| Hypertriglyceridemia c | 31 (8%) | 10 (7%) | 21 (8%) | .657 |
| Hypercholesterolaemia d | 45 (11%) | 17 (12%) | 28 (11%) | .796 |
| Aetiology | ||||
| Viral | 156 (38%) | 60 (41%) | 96 (36%) | .679 |
| ALD | 144 (35%) | 50 (34%) | 94 (36%) | |
| NAFLD or cryptogenic | 69 (17%) | 21 (14%) | 48 (18%) | |
| Other | 42 (10%) | 16 (11%) | 26 (10%) | |
| Varices | 301 (73%) | 107 (73%) | 194 (73%) | .879 |
| Decompensated | 261 (64%) | 96 (65%) | 165 (63%) | .571 |
| History of variceal bleeding | 80 (19%) | 33 (22%) | 47 (18%) | .254 |
| Ascites | ||||
| None | 217 (53%) | 75 (51%) | 142 (54%) | .849 |
| Mild | 144 (35%) | 54 (37%) | 90 (34%) | |
| Severe | 50 (12%) | 18 (12%) | 32 (12%) | |
| History of/current overt hepatic encephalopathy | 115 (28%) | 44 (30%) | 71 (27%) | .511 |
| HVPG, mmHg | 18 (9) | 18.2 (8) | 18 (9) | .084 |
| HVPG 6‐9 mmHg | 41 (10%) | 13 (9%) | 28 (11%) | .76 |
| HVPG 10‐15 mmHg | 102 (25%) | 35 (24%) | 67 (16%) | |
| HVPG ≥ 16 mmHg | 268 (65%) | 99 (67%) | 169 (64%) | |
| MELD, points | 11 (5) | 12 (6) | 11 (6) | .084 |
| CTP score, points | 8 (2) | 8 (2) | 8 (2) | .189 |
| A | 64 (16%) | 20 (14%) | 44 (17%) | .713 |
| B | 259 (63%) | 95 (65%) | 164 (62%) | |
| C | 88 (21%) | 32 (22%) | 56 (21%) | |
| Platelet count, G × L−1 | 98 (72) | 94 (77) | 99 (70) | .881 |
| Albumin, g × L−1 | 35.5 (8.2) | 35.5 (8) | 35.5 (8.3) | .959 |
| Bilirubin, mg × dL−1 | 1.3 (1.47) | 1.25 (1.85) | 1.31 (1.2) | .857 |
| INR | 1.3 (0.3) | 1.3 (0.2) | 1.3 (0.3) | .876 |
| AST, U × L−1 | 52 (46) | 54 (56) | 50 (38) | .502 |
| ALT, U × L−1 | 35 (42) | 36 (42) | 35 (41) | .725 |
| GGT, U × L−1 | 104 (118) | 104 (120) | 104 (119) | .691 |
| CRP, mg × L−1 | 0.28 (0.61) | 0.34 (0.59) | 0.27 (0.62) | .208 |
| VWF, % | 313 (167) | 309 (176) | 318 (164) | .048 |
| Factor VIII e , % | 199 (6) | 198 (85) | 199 (88) | .882 |
| Protein C f , % | 53 (33) | 53 (29) | 54 (36) | .845 |
| Antithrombin g , % | 64 (28) | 61 (23) | 65 (31) | .528 |
| Factor VIII/protein C ratio h | 3.74 (2.74) | 3.74 (2.39) | 3.75 (2.82) | .696 |
Abbreviations: ALD, alcoholic liver disease; ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; CRP, C‐reactive protein; CTP, Child‐Turcotte‐Pugh score; GGT, gamma‐glutamyltransferase; HVPG, hepatic venous pressure gradient; INR, international normalised ratio; MELD, model for end‐stage liver disease; NAFLD, non‐alcoholic fatty liver disease; VWF, von Willebrand factor antigen.
BMI > 25 kg × m−2.
BMI > 30 kg × m−2.
Triglycerides > 150 mg × dL−1.
Total cholesterol > 200 mg × dL−1.
Available in n = 300 patients.
Available in n = 358 patients.
Available in n = 361 patients.
Available in n = 249 patients.